Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
ADMA
#1300
ADMA Biologics, Inc.
15.5
7
+5.49%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+5.49%
Changement Mensuel
-5.98%
Evolution sur 6 mois
-10.05%
Changement Annuel
+1.43%
Clôture Précédente
14.7
6
Open
15.5
7
Bid
Ask
Low
15.5
7
High
15.5
7
Volume
204
Marchés
Actions des Marchés US
Soins de Santé
ADMA
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
121.28 M
195.92 M
222.16 M
228.22 M
237.62 M
238.16 M
—
Valuation ratios
Enterprise value
180.57 M
225.16 M
773.22 M
987.05 M
3.97 B
4.26 B
16.6 B
Price to earnings ratio
—
-2.76
-11.73
-35
21.17
30.4
92.69
Price to sales ratio
—
2.43
4.97
3.95
9.79
8.76
36.07
Price to cash flow ratio
—
-1.75
-12.87
115.81
35.17
88.64
236.52
Price to book ratio
—
1.39
5.04
7.54
11.96
9.36
19.22
Enterprise value to EBITDA ratio
-1.47
-4.2
-23.46
33.77
27.08
21.34
96.18
Profitability ratios
Return on assets %
-0.36
-0.26
-0.19
0.09
0.4
0.24
0.26
Return on equity %
-0.86
-0.51
-0.43
0.21
0.57
0.31
0.35
Return on invested capital %
-237.14
-139.79
-72.03
35.93
81.62
151.01
146.87
Gross margin %
-45.17
1.45
22.89
34.44
51.48
57.39
228.49
Operating margin %
-153.75
-72.12
-25.55
8.38
32.59
37.53
148.57
EBITDA margin %
-291.35
-66.19
-21.39
11.32
34.4
39.09
154.86
Net margin %
-179.41
-88.52
-42.77
10.94
46.35
28.8
114.11
Liquidity ratios
Quick ratio
3.62
2.77
2.73
1.69
2.9
3.74
13.52
Current ratio
7.71
6.87
6.89
5.16
5.97
6.71
25.74
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.25
0.33
0.49
0.76
1.04
0.92
0.93
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.45
0.34
0.41
0.4
0.15
0.11
0.51
Long term debt to total equity ratio
1.05
0.67
0.94
0.97
0.21
0.15
0.69
Per share metrics
Operating cash flow per share
—
-0.81
-0.3
0.04
0.49
0.21
0.21
EBIT per share
—
-0.42
-0.2
0.1
0.57
0.78
0.78
EBITDA per share
—
-0.38
-0.17
0.13
0.6
0.81
0.81
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
0.37
0.44
0.23
0.42
0.36
1.26
Net current asset value per share
—
1.5
1.37
1.15
1.36
1.9
6.6
Tangible book value per share
—
0.97
0.75
0.59
1.42
1.93
6.77
Working capital per share
—
1.28
1.17
0.93
1.13
1.62
5.56
Book value per share
—
1.01
0.77
0.6
1.43
1.95
6.84
Nouvelles
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change
ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance
Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
Le BPA de ADMA Biologics Inc a dépassé les attentes de 0,03$, le CA en dessous des prévisions
ADMA Biologics Inc earnings beat by $0.03, revenue fell short of estimates
Résultats d’ADMA Biologics : l’élan peut-il égaler les objectifs élevés ?
Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026?
Adam Grossman, président d’Adma Biologics, vend pour 337.679$ d’actions
Adam Grossman, president of Adma Biologics, sells $337,679 in shares
Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note